OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income 
Novo Nordisk Shares Tumble After CagriSema Misses Key Trial Endpoint 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
Broadcom Eyes $35 Billion AI Chip Financing Deal With Apollo and Blackstone 
Samsung Shares Slide as Labor Talks Intensify Ahead of Planned Strike 
Dell Stock Hits Record High After Trump Endorsement, AI Server Demand Fuels Rally 
Nintendo Shares Tumble as Weak Forecast and Rising Switch 2 Costs Worry Investors 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
GOP Lawmakers Probe Sam Altman and OpenAI Ahead of Potential IPO 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Democratic Attorneys General Sue Trump Administration Over CDC Childhood Vaccine Schedule Changes 
AcadeMedia Q3 Profit Climbs as International and Adult Education Segments Drive Growth 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
OpenAI-Microsoft Deal Sets $38 Billion Revenue-Sharing Cap Ahead of Potential IPO 
Packaged food manufacturers and fast-food restaurants are preparing for major shifts in consumer demand as appetite-suppressing GLP-1 weight loss pills are expected to enter the U.S. market in early 2025. Analysts believe these oral medications could accelerate long-term changes in eating habits, forcing food companies to reformulate products, adjust portion sizes, and emphasize nutrition-focused offerings.
The U.S. Food and Drug Administration recently approved Novo Nordisk’s Wegovy GLP-1 pill, a milestone that sent shares of several food companies lower. Unlike injectable GLP-1 drugs, the pill form is expected to be cheaper and more appealing to patients who are uncomfortable with injections. Eli Lilly’s competing GLP-1 pill is also anticipated to receive regulatory approval next year, further expanding access to weight loss medications.
As adoption grows, analysts say Americans are likely to reduce consumption of calorie-dense foods such as salty snacks, baked goods, soda, alcohol, and sugary drinks. Instead, demand is shifting toward high-protein, high-fiber, and functional foods that support satiety and portion control. This trend has already been visible with injectable GLP-1 drugs and is expected to intensify with easier-to-use pills.
Research supports this shift. A recent Cornell University study found that households using GLP-1 medications reduced grocery spending by over 5% and fast-food spending by about 8%. While spending rebounded after discontinuing the drugs, experts believe lower-cost pills could encourage longer-term use, broadening the impact across the food industry.
Major companies are responding quickly. Conagra Brands has begun labeling certain Healthy Choice meals as “GLP-1 friendly,” citing faster sales than competing products. Danone reports double-digit growth in high-protein yogurt, while Nestlé has launched new frozen meals tailored to GLP-1 users. Restaurants are also adapting, with chains like Chipotle introducing high-protein menu options and others offering smaller, lower-priced portions.
With nearly 40% of U.S. adults classified as obese and growing interest in weight loss solutions, GLP-1 pills are poised to reshape how Americans eat—and how food companies innovate—for years to come.
